Baby Rabbit Complement
Baby rabbit serum (C12CA) used as a source of complement in a complement bactericidal assay.
Image caption:
Killing of S. Typhimurium by total IgG, IgM and IgA from HIV-uninfected and HIV-infected sera.
Log growth phase S. typhimurium D23580 was added to a mixture of the purified antibodies and 75% BRS. The log10 proportion of the starting number of bacteria remaining after 180 minutes was determined on LB agar. To obtain total antibody of each isotype (IgG, IgM and IgA), serum was incubated sequentially with combinations of human IgA and IgM affinity matrices and protein G affinity matrix to remove IgA, IgM and IgG respectively. Sera used were HIV-uninfected (HIV-ve bactericidal, n = 3), HIV-infected bactericidal (HIV+ve bactericidal, n = 4) and HIV-infected inhibitory (HIV+ve inhibitory, n = 5) sera. Each line represents killing by purified total IgG, IgM or IgA antibodies from one serum. Data shown are from a single representative experiment, where each of the three independent experiments was performed in technical triplicates.
From: Goh YS, Necchi F, O'Shaughnessy CM, Micoli F, Gavini M, Young SP, et al. (2016)
Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
PLoS Negl Trop Dis 10(4): e0004604.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Baby Rabbit complement (C12CA) used as a source of complement for cytotoxicity assays of human leukemic cells.
Image caption:
Anti-CCR7 mAb mediates a strong CDC on T-PLL cells. a CDC on alemtuzumab-naïve patients. Leukemic cells from T-PLL patients (n = 8) were incubated with anti-CCR7, anti-CD52 (alemtuzumab), or an IC at the indicated concentrations and then exposed to rabbit complement for 1.5 h. The percentage of specific cell lysis was determined through quantification of 7-AAD incorporation by flow cytometry. b CDC on alemtuzumab-refractory patients. Specific lysis on T-PLL cells from 4 refractory patients was assayed as described in A. c Relative median fluorescence intensity (RMFI) of CCR7, CD52 and CCR4 in T-PLL cells from alemtuzumab-naïve or alemtuzumab-refractory patients (R/R). Cells obtained from PB samples of patients not treated with alemtuzumab (n = 8; black bars) or refractory to this mAb (n = 4; grey bars) were analyzed by flow cytometry to determine CCR7, CD52, and CCR4 surface density measured as MFI relative to a corresponding IC. d CCR7, CD52, and CCR4 surface expression in T-PLL cells from one representative alemtuzumab-naïve or -refractory patient. E) Proportion of CCR7+, CD52+ and CCR4+ in T-PLL cells from alemtuzumab-naïve or alemtuzumab–refractory patients. The percentage of positive cells was determined in naïve (n = 8; black bars) and refractory patients (n = 4; grey bars). f and g Anti-CCR7 antibody does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC). T-PLL cells were incubated with media alone or in the presence of an IC, anti-CD52 (alemtuzumab) or anti-CCR7 antibodies. f Isolated and IL-2-stimulated human NK cells from a healthy donor were used as effector cells at an effector to target (E:T) ratio of 6:1 (n = 1). g Isolated and IL-2-stimulated wild-type mouse NK cells from spleen (n = 2) were used as effector cells at an effector to target (E:T) ratio of 6:1. After 4 h, the percentage of T-PLL cells killed by ADCC was determined through 7-AAD staining by flow cytometry. In A, B, C, E, F, and G, bars (or symbols) represent mean ± SEM. *, p <0.05; **, p <0.01; ***, p <0.001; ns, not significant
From: Cuesta-Mateos, C., Fuentes, P., Schrader, A. et al.
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Biomark Res 8, 54.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Baby Rabbit complement (C12CA) used for the depletion of primary CAR-T cells in combination with Rituximab.
Image caption:
RTX-dependent depletion of primary T-cells transiently expressing CAR architectures followed by flow cytometry. Representative examples of flow cytometry data obtained after incubating T-cells transiently expressing C1, C5 or C14 in the presence or in the absence of RTX and complement for 150 min at 37°C. Following the treatment, T-cells were labeled by Efluor780 and analyzed by flow cytometry by looking at viable CAR+ T-cells among singlets (gating strategy: singlets>CAR+ T-cells>viability).
From: Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, Duclert A, Sasu BJ, Duchateau P, Poirot L.
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.
Sci Rep. 2018 Jun 12;8(1):8972.
doi: 10.1038/s41598-018-27264-w.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity studies.
Product Details
- Product Form
- Pack Size: 2 mlBaby rabbit serum - lyophilisedPack Size: 1 mlBaby rabbit serum - lyophilized
- Reconstitution
- Pack Size: 2 mlReconstitute with 2ml ice cold distilled waterPack Size: 1 mlReconstitute with 1.0 ml ice cold distilled water
- Preservative Stabilisers
- None present
Storage Information
- Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC for 1 hour or aliquot and store at -70oC for longer.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- Guaranteed until date of expiry. Please see product label.
More Information
- Regulatory
- For research purposes only
Applications of Baby Rabbit Complement
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Functional Assays 1 | |||
| Immunoassay |
- 1 This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Instructions For Use
- Use within one hour of reconstitution, keeping on ice throughout.
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Product Specific References
References for Baby Rabbit Complement
-
Council of Europe. (1983) Essential aspects of tissue typing: Preparation, use, storage of reagents and standardisation of complement.
European Health Committee, Strasbourg, ISBN 92-871.224-4. -
Edited by J.G.Ray. (1979) NIAID Manual of tissue typing techniques.
Publication No. NIH-80-545. -
Anderson, L.D. Jr et al. (1999) Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Cancer Res. 59 (7): 1525-30. -
Mason, J.C. et al. (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Circ Res. 91 (8): 696-703. -
Lidington, E.A. et al. (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
Blood. 96 (8): 2784-92. -
De clercq, L. et al. (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue.
J Anim Sci. 75 (7): 1791-7. -
Hung, M.C. et al. (2011) The Neisseria meningitidis Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate.
Infect Immun. 79: 3784-91. -
Lee, S.J. et al. (2012) Identification of a common immune signature in murine and human systemic Salmonellosis.
Proc Natl Acad Sci U S A. 109 (13): 4998-5003. -
Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing.
J Immunol Methods. 387 (1-2): 121-9. -
Li, S.H. et al. (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells.
Circulation. 109: 833-6. -
Hyams, C. et al. (2010) Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype.
Infect Immun. 78: 716-25. -
Newcombe, J. et al. (2004) Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.
Infect Immun. 72: 338-44. -
Mason, J.C. et al. (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
Am J Physiol Cell Physiol. 282: C578-87. -
Sancho, D. et al. (2006) CD69 targeting differentially affects the course of collagen-induced arthritis.
J Leukoc Biol. 80: 1233-41. -
Hung MC et al. (2013) The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential.
MBio. 4 (2): pii: e00041-13. -
Goh YS et al. (2016) Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
PLoS Negl Trop Dis. 10 (4): e0004604. -
Sawant S et al. (2016) Establishment of 3D Co-Culture Models from Different Stages of Human Tongue Tumorigenesis: Utility in Understanding Neoplastic Progression.
PLoS One. 11 (8): e0160615. -
Humbert MV et al. (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.
PLoS One. 11 (8): e0160403. -
Nganje, C.N. et al. (2019) PepN is a non-essential, cell wall-localized protein that contributes to neutrophil elastase-mediated killing of Streptococcus pneumoniae.
PLoS One. 14 (2): e0211632. -
Dierckx de Casterlé I et al. (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.
Cancer Immunol Immunother. 67 (4): 589-603. -
Cuesta-Mateos, C. et al. (2020) CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Biomarker Research.8, 54. -
Valton, J. et al. (2018) A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.
Sci Rep. 8 (1): 8972.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
